LeAnn Norris to Hematinics
This is a "connection" page, showing publications LeAnn Norris has written about Hematinics.
Connection Strength
0.646
-
Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. Am J Ther. 2018 Nov/Dec; 25(6):e670-e674.
Score: 0.146
-
Reply to A.M. Zeidan et al. J Clin Oncol. 2017 10 01; 35(28):3265.
Score: 0.134
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
Score: 0.132
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
Score: 0.132
-
Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opin Emerg Drugs. 2013 Dec; 18(4):421-9.
Score: 0.102